Takuya Akashi
Kyushu University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Takuya Akashi.
Journal of Cardiac Failure | 2016
Akiko Nishizaki; Kazuo Sakamoto; Keita Saku; Kazuya Hosokawa; Takafumi Sakamoto; Yasuhiro Oga; Takuya Akashi; Yoshinori Murayama; Takuya Kishi; Tomomi Ide; Kenji Sunagawa
BACKGROUND Although vagal nerve stimulation (VNS) benefits patients with chronic heart failure (CHF), the optimal dose of VNS remains unknown. In clinical trials, adverse symptoms limited up-titration. In this study, we evaluated the impact of various voltages of VNS which were titrated below symptom threshold on cardiac function and CHF parameters in rat myocardial infarction (MI) models. METHODS AND RESULTS We randomly allocated MI rats to vagal (VNS; n = 41) and sham (Sham; n = 16) stimulation groups. We stimulated the right vagal nerve with 20 Hz at 3 different voltages for 4 weeks. We defined Max as the highest voltage that did not evoke any symptom, Half as one-half of Max, and Quarter as one-fourth of Max. All 3 VNS groups significantly reduced biventricular weight compared with Sham (P < .05). In contrast, only Half decreased left ventricular (LV) end-diastolic pressure (Half: 17.5 ± 2.0 mm Hg; Sham: 24.2 ± 1.2 mm Hg; P < .05) and increased LV ejection fraction (Half: 37.9 ± 3.1%; Sham: 28.4 ± 2.3%,-P < .05) and LV maximum +dP/dt (Half: 5918.6 ± 2.0 mm/Hg/s; Sham: 5001.2 ± 563.2 mm Hg/s; P < .05). The number of large vagal nerve fibers was reduced with Max (Max: 163.1 ± 43.0 counts/bundle; Sham: 360.0 ±61.6 counts/bundle; P < .05), indicating significant neural damage by VNS. CONCLUSION The optimal titration of VNS would maximize benefits for CHF and minimize adverse effects.
American Journal of Physiology-heart and Circulatory Physiology | 2017
Takamori Kakino; Keita Saku; Takafumi Sakamoto; Kazuo Sakamoto; Takuya Akashi; Masataka Ikeda; Tomomi Ide; Takuya Kishi; Hiroyuki Tsutsui; Kenji Sunagawa
Left ventricular assist device (LVAD) saves lives in patients with severe left ventricular (LV) failure. However, predicting how much LVAD boosts total cardiac output (CO) remains difficult. This study aimed to develop a framework to quantitatively predict the impact of LVAD on hemodynamics. We adopted the circulatory equilibrium framework and incorporated LVAD into the integrated CO curve to derive the circulatory equilibrium. In anesthetized dogs, we ligated left coronary arteries to create LV failure and inserted a centrifugal pump as LVAD. Using CO and right (PRA) and left atrial pressure (PLA) measured before LVAD support, we predetermined the stressed volume (V) and logarithmic slope of right heart CO curve (SR). Next, we initiated LVAD at maximum level and then decreased LVAD flow stepwise while monitoring hemodynamic changes. We predicted LVAD-induced CO and PRA for given PLA from the predetermined SR and V and compared with those measured experimentally. The predicted CO [r2 = 0.907, SE of estimate (SEE) = 5.59 ml·min-1·kg-1, P < 0.001] and PRA (r2 = 0.967, SEE = 0.307 mmHg, P < 0.001) matched well with measured values indicating the validity of the proposed framework. We further conducted simulation using the validated framework to analyze the impact of LVAD on PRA under various right ventricular (RV) functions. It indicated that PRA is relatively insensitive to changes in RV end-systolic elastance or pulmonary arterial resistance, but sensitive to changes in V. In conclusion, the circulatory equilibrium framework predicts quantitatively the hemodynamic impact of LVAD. This knowledge would contribute to safe management of patients with LV failure undergoing LVAD implantation. NEW & NOTEWORTHY Hemodynamic response to left ventricular assist device (LVAD) has not been quantitatively investigated. This is the first report of quantitative prediction of the hemodynamics on LVAD using circulatory equilibrium framework. The validated framework allows us to simulate the impact of LVAD on right atrial pressure under various right ventricular functions.
Journal of the American College of Cardiology | 2015
Takahiro Arimura; Keita Saku; Takamori Kakino; Takuya Akashi; Takuya Nishikawa; Yoshinori Murayama; Takako Takehara; Takeshi Toyama; Tomomi Ide; Takuya Kishi; Kenji Sunagawa
Although vagal nerve stimulation (VNS) in the acute phase of AMI has a powerful anti-ischemic effect, technical difficulties associated with VNS preclude its application under emergency clinical settings. Furthermore, how the acute phase VNS translates into the long term benefit remains unknown. In
Journal of Cardiac Failure | 2014
Takahiro Arimura; Keita Saku; Takamori Kakino; Takuya Akashi; Yoshinori Murayama; Takako Takehara; Tomomi Ide; Takuya Kishi; Kenji Sunagawa
European Heart Journal | 2013
Keita Saku; Takamori Kakino; Kazuo Sakamoto; Takafumi Sakamoto; Takuya Akashi; Yuko Hata; Takuya Kishi; Tomomi Ide; Kenji Sunagawa
European Heart Journal | 2018
Keimei Yoshida; Keita Saku; Kazuhiro Kamada; Kiyokazu Abe; Takuya Akashi; Takuya Kishi; Hiroyuki Tsutsui; Kenji Sunagawa
Journal of Cardiac Failure | 2017
Genya Sunagawa; Keita Saku; Takuya Akashi; Takuya Kishi; Hiroyuki Tsutsui; Kenji Sunagawa
European Heart Journal | 2017
Genya Sunagawa; Keita Saku; Takahiro Arimura; Takuya Akashi; Yoshinori Murayama; Takafumi Sakamoto; Takuya Kishi; Kenji Sunagawa; Hiroyuki Tsutsui
European Heart Journal | 2017
Keimei Yoshida; Keita Saku; Kazuhiro Kamada; Kiyokazu Abe; M. Tanaka; Takuya Akashi; Takuya Kishi; Kenji Sunagawa; Hiroyuki Tsutsui
Circulation | 2017
Keimei Yoshida; Keita Saku; Kazuhiro Kamada; Mariko Tanaka; Takuya Akashi; Kohtaro Abe; Takuya Kishi; Kenji Sunagawa; Hiroyuki Tsutsui